Effects of XXXX on postoperative @entity1643 and functional outcomes after lumbar open discectomy: a triple-blind, randomized placebo-controlled trial.

@entity1 @entity1643 @entity137 @entity6693 @entity158 @entity282
UNASSIGNED: OBJECT Despite advances in surgical and anesthesiology techniques, many @entity1 continue to experience @entity282 after lumbar disc operations. This study aims to investigate the effects of @entity6693 (MB) on preventing postoperative @entity1643 ( @entity1643 ) with or without @entity158 and improving the quality of life (QOL) in @entity1 undergoing lumbar open discectomy. METHODS This is a prospective, randomized, triple-blind, placebo-controlled clinical trial, which was conducted at Shiraz University of Medical Sciences between July 2011 to January 2012. Of a total of 130 @entity1 , 115 were eligible for participation; 56 received 1 ml of MB solution at a concentration of 0.5% (MB group) and 59 received an equivalent volume of normal saline (control group). Primary outcomes were the control of @entity1643 with or without @entity158 , which was evaluated preoperatively and at 24 hours and 3 months after surgery with the use of a visual analog scale (VAS), and the improvement of QOL, which was assessed preoperatively and 3 months postoperatively by means of the Persian translation of the Oswestry Disability Index questionnaire. RESULTS The mean VAS scores for @entity1643 were significantly lower in the MB group compared with the control group at 24 hours (1.25    0.97 vs 2.80    0.69, p < 0.001) and 3 months (1.02    1.29 vs 2.07    1.10, p = 0.019) after treatment. The mean @entity158 scores decreased significantly in the 2 groups at 24 hours after surgery, but the mean @entity158 score was significantly lower in the MB-treated @entity1 than the control group. However, the difference between @entity158 scores in the MB group (1    1.1) and the control group (1.2    1) was not statistically significant (p = 0.64). The reduction in @entity1643 was greater in the MB group than the control group (8.11    1.74 vs 6.07    1.52, p = 0.023, CI 95% -1.37 to -0.10). The functional QOL improved significantly 3 months after the operation in both groups (p < 0.001). Moderate disability occurred more frequently in the control group than in the MB group (14.5% vs 7.7%, p = 0.004). No @entity137 , adverse effects, or complications were found in the group of @entity1 treated with MB injection. CONCLUSIONS A single dose of MB (1 ml 0.5%) for coating the dura and surrounding tissues (facet and muscle) shows promising results in terms of safety, reduction of @entity282 , and functional outcome compared with placebo.
